PULSE BIOSCIENCES, INC. Q4 FY2024 earnings call

• Paul LaViolette introduced himself as the new CEO and discussed his background in MedTech, expressing excitement about Pulse Biosciences' nanosecond PFA technology. • Progress in early commercialization steps of Percutaneous Electrode for benign thyroid diseases, clinical feasibility studies with surgical clamp for atrial fibrillation and 360 Catheter for atrial fibrillation. • Nanosecond PFA technology details, including its non-thermal nature, faster treatment times, and unique mechanism of action. • Achievements like 7 FDA clearances, treated 6,000 patients, FDA breakthrough device designation for cardiac surgical clamp, and commercializing first treatment in soft tissue ablation. • Updates on specific products: Percutaneous Electrode's potential in benign thyroid nodules with positive clinical data from Italian study and U.S. pilot program; surgical ablation clamp's first feasibility study in Europe with 30 patients treated and preclinical study results published; 360 Catheter system's differentiation in AF ablation with promising early human feasibility study results. • Jon Skinner discussed fourth quarter 2024 financial results, noting increase in GAAP costs and expenses, changes in non-GAAP measures, and strengthening of balance sheet via warrant exercises.

No specific segment performance data provided in absolute terms and revenue contribution % as per the transcript.

• Plan to submit a formal IDE to the FDA for the cardiac surgical clamp pivotal clinical study by mid-year and commence the trial. • Intention to provide an update on first quarter performance in a call scheduled for early May.

• Forward-looking statements may differ from actual results due to certain risks and uncertainties, detailed in press release and SEC filings. No specific operational failures discussed in detail.

Q: No questions were raised during the call A: No questions were asked